J&J’s $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Spravato, the ketamine-derived nasal spray from Johnson & Johnson, was once seen as a long shot. It was difficult to deliver, heavily regulated and slow to catch on. Find out how it became a billion-dollar drug and part of a new model for treating depression.

Watch more mini documentaries from Bloomberg: https://www.youtube.com/playlist?list=PLGaYlBJIOoa_EzzMpticURNR29AiQi10v

The $1.7 Billion Trip: https://www.bloomberg.com/features/2026-jjs-spravato-psychedelic-blockbuster-drug/

How J&J leveraged insurance to turn Spravato into a blockbuster depression drug.

Like this video? Subscribe and turn on notifications so you don’t miss any videos from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9
Visit http://www.bloomberg.com for business news & analysis, up-to-the-minute market data, features, profiles and more.

#Ketamine #Science #Business

source